AstraZeneca's Brilinta Met Primary Endpoint in Phase Three Stroke Trial
January 27 2020 - 2:54AM
Dow Jones News
By Adriano Marchese
AstraZeneca PLC (AZN.LN) said Monday that its drug Brilinta met
the primary endpoint in a phase three trial for stroke
prevention.
The British pharmaceutical major said high-level results from
the phase three THALES trial showed Brilinta used twice daily with
aspirin reached a statistically significant reduction in the risk
of the primary composite endpoint of stroke and death.
"Results of the Phase three THALES trial showed Brilinta, in
combination with aspirin, improved outcomes in patients who had
experienced a minor acute ischaemic stroke or high-risk transient
ischaemic attack," Executive Vice President of BioPharmaceuticals
R&D Mene Pangalos said.
Write to Adriano Marchese at adriano.marchese@wsj.com
(END) Dow Jones Newswires
January 27, 2020 02:39 ET (07:39 GMT)
Copyright (c) 2020 Dow Jones & Company, Inc.
AstraZeneca (NYSE:AZN)
Historical Stock Chart
From Mar 2024 to Apr 2024
AstraZeneca (NYSE:AZN)
Historical Stock Chart
From Apr 2023 to Apr 2024